Key points are not available for this paper at this time.
Metformin may be associated with a decreased risk of many cancer types, but high heterogeneity and risk of publication bias limit confidence in these results. Additional studies in populations without diabetes are needed to better understand the utility of metformin in cancer prevention.
O’Connor et al. (Tue,) studied this question.